Zaloguj się

Gotowe bibliografie tematyczne / Access to prophylaxis / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Access to prophylaxis.

Artykuły w czasopismach na temat „Access to prophylaxis”

Autor: Grafiati

Data publikacji: 2 czerwca 2025

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Access to prophylaxis”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Kovalik, Eugene C., and Steve J. Schwab. "Antibiotic prophylaxis for hemodialysis access placement." American Journal of Kidney Diseases 30, no. 3 (1997): 448. http://dx.doi.org/10.1016/s0272-6386(97)90294-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Kaladharan, Sid, and Melissa Warner. "HIV- PEP (Post Exposure Prophylaxis) Access Project." International Journal of Integrated Care 17, no. 3 (2017): 87. http://dx.doi.org/10.5334/ijic.3199.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Krakower, Douglas, and Julia L. Marcus. "Commercial Determinants of Access to HIV Preexposure Prophylaxis." JAMA Network Open 6, no. 11 (2023): e2342759. http://dx.doi.org/10.1001/jamanetworkopen.2023.42759.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Barnett, Daniel, and Danielle Nance. "A Retrospective Analysis and Characterization of Female Patients with Bleeding Disorders Hemophilia B, Hemophilia B and Von Willebrand's Disease and Their Treatment Type at Banner MD Anderson Cancer Center." Blood 142, Supplement 1 (2023): 1254. http://dx.doi.org/10.1182/blood-2023-187656.

Pełny tekst źródła

Streszczenie:

Introduction: Women with bleeding disorders experience bleeding in mucocutaneous tissues, uterine bleeding, and in muscles and joints. In men, bleeding of more than 1 or 2 bleeds per year is justification for starting prophylaxis with factor and non-factor replacement therapy. At Banner MD Anderson Cancer Center (BMDACC), women are offered prophylaxis according to the same standard. Uterine bleeding classified as excessive or disruptive to daily activity is considered bleeding requiring prophylaxis. Aim: Describe the number of women in the bleeding disorder database from June 2018 to December

Style APA, Harvard, Vancouver, ISO itp.

5

Keferstein, Rolf D., Cornelia Fiedler, Fritz W. Pelster, and Berthold Reers. "Infection Prophylaxis and Infection Control in Vascular Access Surgery." Vascular Surgery 26, no. 4 (1992): 300–306. http://dx.doi.org/10.1177/153857449202600408.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Salman, Loay, and Arif Asif. "Antibiotic Prophylaxis: Is it Needed for Dialysis Access Procedures?" Seminars in Dialysis 22, no. 3 (2009): 297–99. http://dx.doi.org/10.1111/j.1525-139x.2009.00607.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Fennell, Jérôme Patrick, Martin O'Donohoe, Martin Cormican, and Maureen Lynch. "Linezolid lock prophylaxis of central venous catheter infection." Journal of Medical Microbiology 57, no. 4 (2008): 534–35. http://dx.doi.org/10.1099/jmm.0.47665-0.

Pełny tekst źródła

Streszczenie:

Central venous catheter (CVC)-related infections are a major problem for patients requiring long-term venous access and may result in frequent hospital admissions and difficulties in maintaining central venous access. CVC-related blood stream infections are associated with increased duration of inpatient stay and cost approximately \#8364;13 585 per patient [Blot, S. I., Depuydt, P., Annemans, L., Benoit, D., Hoste, E., De Waele, J. J., Decruyenaere, J., Vogelaers, D., Colardyn, F. & Vandewoude, K. H. (2005). Clin Infect Dis 41, 1591–1598]. Antimicrobial lock therapy may prevent CVC-relate

Style APA, Harvard, Vancouver, ISO itp.

8

McBride, Ali, Karen MacDonald, and Ivo Abraham. "Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma." Blood 136, Supplement 1 (2020): 24–25. http://dx.doi.org/10.1182/blood-2020-136810.

Pełny tekst źródła

Streszczenie:

Introduction: Costs of prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) have been reduced in recent years by the approval of several biosimilar filgrastim and pegfilgrastim agents. The savings from conversion to biosimilars can be reallocated to provide expanded access to CIN/FN prophylaxis or anti-neoplastic treatment. To illustrate this, we simulated in a panel of 20,000 non-Hodgkin lymphoma (NHL) patients: 1) the savings that could be realized from CIN/FN prophylaxis with biosimilar pegfilgrastim-cbqv over reference pegfilgrastim with or without on-body injector (PEG/PEG-O

Style APA, Harvard, Vancouver, ISO itp.

9

Sadowski, Maciej. "The strategy of long-term central venous access infection prophylaxis." Zakażenia XXI wieku 2018, no. 5 (2018): 253–58. http://dx.doi.org/10.31350/zakazenia/2018/5/z2018039.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Landers, Stewart, and Farzana Kapadia. "Preexposure Prophylaxis: Adapting HIV Prevention Models to Achieve Worldwide Access." American Journal of Public Health 107, no. 10 (2017): 1534–35. http://dx.doi.org/10.2105/ajph.2017.304035.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Marcus, Julia L., and Douglas S. Krakower. "Working Toward Broad and Equitable Access to HIV Preexposure Prophylaxis." American Journal of Public Health 109, no. 9 (2019): 1160–61. http://dx.doi.org/10.2105/ajph.2019.305254.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Wong, Keith Yiu Kei, and Jeffrey D. Klausner. "Geographic Access to Preexposure Prophylaxis and the Case for Telemedicine." American Journal of Public Health 110, no. 1 (2020): e3-e3. http://dx.doi.org/10.2105/ajph.2019.305401.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Phillips, Andrew N., Euphemia Sibanda, Kenly Sikwese, et al. "Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa." AIDS 36, no. 10 (2022): 1473–75. http://dx.doi.org/10.1097/qad.0000000000003258.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Choudhury, Devasmita. "HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Vascular Access Thrombosis Prophylaxis." Seminars in Dialysis 19, no. 4 (2006): 335–42. http://dx.doi.org/10.1111/j.1525-139x.2006.00182.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Botwin, Kimberly J., Jeannie Chan, Richard Jacobs, and B. Joseph Guglielmo. "Restricted access to automated dispensing machines for surgical antimicrobial prophylaxis." American Journal of Health-System Pharmacy 58, no. 9 (2001): 797–99. http://dx.doi.org/10.1093/ajhp/58.9.797.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Nogara, Bibiana Letícia, Jarbas da Silva Ziani, Mileny Rosalina Galvão, et al. "Sociodemographic profile of users and discontinuation rate of HIV pre-exposure Prophylaxis after the expansion of access." Revista Eletrônica Acervo Saúde 24, no. 12 (2024): e17866. https://doi.org/10.25248/reas.e17866.2024.

Pełny tekst źródła

Streszczenie:

Objective: To evaluate whether there was a change in the sociodemographic profile of users of Pre-exposure Prophylaxis (PrEP) for HIV and in the discontinuation/abandonment rate after the expansion of access to the entire population at increased risk of infection. Methods: This is a retrospective cross-sectional study conducted with 180 (Group 1) and 205 (Group 2) users who started PrEP before and after the expansion of access, respectively. Results: Both groups presented the same sociodemographic profile, characterized by men, cisgender, homosexual, white, aged between 18 and 24 years, with m

Style APA, Harvard, Vancouver, ISO itp.

17

McBride, Ali, Karen MacDonald, and Ivo Abraham. "Cost efficiency and budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN):Simulation modeling in metastatic pancreatic cancer." Journal of Clinical Oncology 39, no. 3_suppl (2021): 441. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.441.

Pełny tekst źródła

Streszczenie:

441 Background: Biosimilars have contributed to the reduction in the cost of prophylaxis of CIN/FN in recent years. Savings generated from conversion to biosimilars could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to anti-neoplastic treatment. To demonstrate this, we simulated: 1) the savings that could be realized from CIN/FN prophylaxis with biosimilar pegfilgrastim-cbqv (BIOSIM-PEG) over reference pegfilgrastim with or without on-body injector (PEG/PEG-OBI), 2) a model of expanded access to BIOSIM-PEG from cost-savings achieved from conv

Style APA, Harvard, Vancouver, ISO itp.

18

McBride, Ali, Karen MacDonald, and Ivo Abraham. "Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19372-e19372. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19372.

Pełny tekst źródła

Streszczenie:

e19372 Background: Biosimilars have the potential to reduce the cost of prophylaxis of CIN/FN. To demonstrate this, we: 1) conducted a US comparative cost-efficiency analysis of CIN/FN prophylaxis with biosimilar pegfilgrastim-cbqv over reference pegfilgrastim without or with on-body injector (PEG/PEG-OBI), 2) modeled budget-neutral expanded access to biosimilar pegfilgrastim-cbqv from cost-savings achieved from conversion from PEG/PEG-OBI, and 3) estimated the number-needed-to-convert (NNC) to biosimilar pegfilgrastim-cbqv from PEG/PEG-OBI to purchase one additional treatment of biosimilar pe

Style APA, Harvard, Vancouver, ISO itp.

19

Olifant, Lerato L., Edith Phalane, and Refilwe N. Phaswana-Mafuya. "Innovative pre-exposure prophylaxis interventions among adolescent girls and young women during COVID-19 lockdown period in sub-Saharan Africa: A systematic review." African Journal of Reproductive Health 28, no. 9 (2024): 191–213. http://dx.doi.org/10.29063/ajrh2024/v28i9.18.

Pełny tekst źródła

Streszczenie:

Adolescent girls and young women are key, and priority populations impacted by a higher risk of acquiring human immunodeficiency virus. In 2015, pre-exposure prophylaxis was introduced as a biomedical human immunodeficiency virus prevention tool. However, its uptake continues to be lower in sub-Saharan countries, particularly among adolescent girls and young women. The uptake may have worsened during the Coronavirus disease 2019 lockdown restrictions. Innovative interventions to improve its uptake were implemented, this review aimed to identify and describe these interventions in sub-Saharan A

Style APA, Harvard, Vancouver, ISO itp.

20

Agada, Simon J,. "Barriers to Uptake of Oral Pre-exposure Prophylaxis for HIV among Adolescents’ Young boys and Girls an Assessment of Cross River North Nigeria." TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH 11, no. 2 (2023): 281–90. http://dx.doi.org/10.21522/tijph.2013.11.02.art026.

Pełny tekst źródła

Streszczenie:

Antiretroviral pre-exposure prevention (PrEP) to stop HIV transmission was 1st approved by the USA Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest wherever PrE-exposure prophylaxis has been deployed, the uptake of PrE-exposure prophylaxis is insulant, significantly among populations with disproportionate HIV burden. This narrative review seeks to spot individual and general barriers to PrE-exposure prophylaxis usage in African country. A comprehensive search of recent literature uncovered a fancy array of structural, social, clinical

Style APA, Harvard, Vancouver, ISO itp.

21

McBride, Ali, Karen MacDonald, and Ivo Abraham. "Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19371-e19371. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19371.

Pełny tekst źródła

Streszczenie:

e19371 Background: Biosimilars not only have the potential to reduce the cost of prophylaxis of CIN/FN but such savings could be reallocated to provide access to anti-neoplastic treatment. To demonstrate this, we simulated in a 20,000-patient panel: 1) the savings that could be realized from CIN/FN prophylaxis with biosimilar pegfilgrastim-cbqv over reference pegfilgrastim with or without on-body injector (PEG/PEG-OBI), 2) a model of expanded access to adjuvant chemotherapy with doxorubicin/cyclophosphamide for localized breast cancer from cost-savings achieved from conversion from PEG/PEG-OBI

Style APA, Harvard, Vancouver, ISO itp.

22

Gandhi, Monica. "Long-acting ART and preexposure prophylaxis: profound promise but stunted access." Current Opinion in HIV and AIDS 20, no. 1 (2024): 1–3. https://doi.org/10.1097/coh.0000000000000902.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Zibari, Gazi B., Merit F. Gadallah, Michael Landreneau, et al. "Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections." American Journal of Kidney Diseases 30, no. 3 (1997): 343–48. http://dx.doi.org/10.1016/s0272-6386(97)90277-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Mir, Joan Francesc, Manuel F. Mazarío, and Pep Coll. "Implementation models and access to HIV pre-exposure prophylaxis in Spain." Enfermedades infecciosas y microbiologia clinica (English ed.) 38, no. 5 (2020): 234–37. http://dx.doi.org/10.1016/j.eimce.2019.05.012.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Krakower, Douglas, and Julia L. Marcus. "Free the PrEP — Over-the-Counter Access to HIV Preexposure Prophylaxis." New England Journal of Medicine 389, no. 6 (2023): 481–83. http://dx.doi.org/10.1056/nejmp2305644.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Brundrett, Megan E. "Human Immunodeficiency Virus Preexposure Prophylaxis in Adolescents and Young Adults." Pediatrics In Review 43, no. 1 (2022): 28–36. http://dx.doi.org/10.1542/pir.2020-002048.

Pełny tekst źródła

Streszczenie:

Human immunodeficiency virus (HIV) prevention holds the promise of decreasing the burden of HIV infections worldwide. Access to HIV prevention services, including preexposure prophylaxis (PrEP), is a key strategy in reducing HIV transmission, but it continues to be underused. PrEP, a once-daily medication for HIV prevention, is approved for adolescents. A pediatrician’s role is critical in identifying and increasing access for adolescents and young adults to PrEP services and reducing HIV acquisition in youth.

Style APA, Harvard, Vancouver, ISO itp.

27

Solano, M. H., A. Linares, C. Sossa, et al. "Secondary prophylaxis with anti-inhibitor coagulant complex (AICC) : from anecdote to reality." Revista Colombiana de Hematología y Oncología 4, no. 2 (2017): 37. http://dx.doi.org/10.51643/22562915.231.

Pełny tekst źródła

Streszczenie:

Background. Evidence of prophylaxis benefit in patients without inhibitors to reduce hemarthrosis and severe bleeding have not been demonstrate in patients with hemophilia A (HA) and inhibitors, however, we could assume the reduction in bleeding episodes. Several publications have shown good results of secondary prophylaxis with AICC agents to reduce safely the number of bleeding events. We report the results in hemophilia treatment centers of two cities in a developing country, with access difficulties related to the high cost of this therapy to the health system. Objective. To describe the f

Style APA, Harvard, Vancouver, ISO itp.

28

West, Victoria. "Use of arteriovenous fistula in children with bleeding disorders." Journal of Haemophilia Practice 3, no. 2 (2016): 74–77. http://dx.doi.org/10.17225/jhp00087.

Pełny tekst źródła

Streszczenie:

Abstract Haemophilia and associated bleeding disorders are chronic conditions that require easy, accessible, and reliable venous access for treatment. Peripheral venous access is traditionally the first option considered for prophylaxis. The initial introduction of prophylaxis to a child is during the first two years of life, and peripheral access can be problematic. Central venous catheters (CVC), for example port-a-caths, are widely used among this group; however, these devices require surgical insertion and are not without their own complications. Data were collected on venous access method

Style APA, Harvard, Vancouver, ISO itp.

29

Windyga, Jerzy. "Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia?" Seminars in Thrombosis and Hemostasis 42, no. 05 (2016): 533–40. http://dx.doi.org/10.1055/s-0036-1579639.

Pełny tekst źródła

Streszczenie:

Long-term (or continuous) prophylaxis is generally accepted as the best form of treatment for patients with severe hemophilia A and B. Results of recent prospective, randomized clinical trials, as well as observational studies performed in the last decades, have provided strong and convincing evidence that continuous prophylaxis leads to reduction in the number of bleeding episodes, better joint status and improved health-related quality of life as compared with on-demand (or episodic) treatment. Nevertheless, many questions regarding long-term prophylaxis still remain open, for instance: when

Style APA, Harvard, Vancouver, ISO itp.

30

Pokharel, Prenit Kumar, and Shrijana Chapagain. "Awareness among the Dental students and Dental Interns of Kantipur Dental College and Hospital regarding Antibiotics Prophylaxis for Infective Endocarditis." Journal of College of Medical Sciences-Nepal 15, no. 2 (2019): 112–18. http://dx.doi.org/10.3126/jcmsn.v15i2.22162.

Pełny tekst źródła

Streszczenie:

Background: Infective Endocarditis is relatively a rare disease and is believed to be caused by the vegetative growth on the previously damaged or congenitally malformed cardiac valves or endocardium. Several factors determines that the dentist practicing prophylaxis measures, the foremost important one is the knowledge which is taught to them during dental school, which is the main reason to conduct this study to test the awareness among the dental students of Kantipur Dental College and Hospital, Kathmandu regarding the prophylaxis guideline awareness. Methods: BDS Third, Fourth, Fifth

Style APA, Harvard, Vancouver, ISO itp.

31

Kabami, Jane, Catherine A. Koss, Helen Sunday, et al. "Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya." JAIDS Journal of Acquired Immune Deficiency Syndromes 95, no. 5 (2024): 447–55. http://dx.doi.org/10.1097/qai.0000000000003383.

Pełny tekst źródła

Streszczenie:

Background: Pregnant and postpartum women in Sub-Saharan Africa are at high risk of HIV acquisition. We evaluated a person-centered dynamic choice intervention for HIV prevention (DCP) among women attending antenatal and postnatal care. Setting: Rural Kenya and Uganda. Methods: Women (aged 15 years or older) at risk of HIV acquisition seen at antenatal and postnatal care clinics were individually randomized to DCP vs. standard of care (SEARCH; NCT04810650). The DCP intervention included structured client choice of product (daily oral pre-exposure prophylaxis or postexposure prophylaxis), servi

Style APA, Harvard, Vancouver, ISO itp.

32

Mahlangu, J., F. Bassa, M. Bassingthwaighte, et al. "Prophylaxis is the new standard of care in patients with haemophilia." South African Medical Journal 112, no. 6 (2022): 405–8. http://dx.doi.org/10.7196/samj.2022.v112i6.16362.

Pełny tekst źródła

Streszczenie:

Randomised controlled clinical trial evidence on prophylaxis as optimal care for patients with haemophilia was generated more than a decade ago. However, this knowledge has not translated into clinical practice in South Africa (SA) owing to many barriers to prophylaxis. These include the high treatment burden imposed by prophylaxis (frequent injections two to four times a week), the need for intravenous access to administer replacement clotting factor therapies, and the higher volume of clotting factor required compared with episodic treatment. The recently introduced non-factor therapies in h

Style APA, Harvard, Vancouver, ISO itp.

33

Oredo, Pascal O., Harun M. Kimani, and Judy Mugo. "Access to reproductive health services by female survivors of sexual gender-based violence: a descriptive cross-sectional study of Nairobi City County, Kenya." International Journal Of Community Medicine And Public Health 11, no. 9 (2024): 3348–54. http://dx.doi.org/10.18203/2394-6040.ijcmph20242530.

Pełny tekst źródła

Streszczenie:

Background: Sixty percent of women globally are exposed to reproductive health problems related to sexual gender-based violence. In Kenya, sexual violence is one of the top 10 risk factors for disease burden. The study aimed to determine access to reproductive health services by female survivors of sexual gender-based violence in Nairobi city county, Kenya. Methods: The study adopted descriptive cross-sectional design using pretested questionnaires. Study population was 269 female survivors of sexual gender-based violence. Data was analysed thematically and presented by use of percentages and

Style APA, Harvard, Vancouver, ISO itp.

34

Sutarsa, I. Nyoman. "Where do we go with HIV pre-exposure prophylaxis in Indonesia?" Public Health and Preventive Medicine Archive 5, no. 2 (2017): 77. http://dx.doi.org/10.15562/phpma.v5i2.17.

Pełny tekst źródła

Streszczenie:

Mantled by discrimination and exclusion, HIV/AIDS became a major epidemic of present-day globalization. Access to antiretroviral therapy (ART) and numerous preventative measures have resulted in reduced mortality and morbidity rates.1 However, the burden of disease associated with HIV infection remains tremendous. Total number of people living with HIV in 2016 were 36.7 million. PrEP is an effective additional prevention strategy at trial settings. Decision to adopt PrEP as a public health intervention must be made based on the need and capacity of current systems. Instead of allocating substa

Style APA, Harvard, Vancouver, ISO itp.

35

Takahashi, Daijiro, Tomohiko Nakamura, Reiko Shigematsu, et al. "Fosfluconazole for Antifungal Prophylaxis in Very Low Birth Weight Infants." International Journal of Pediatrics 2009 (2009): 1–3. http://dx.doi.org/10.1155/2009/274768.

Pełny tekst źródła

Streszczenie:

We conducted a retrospective case series study to evaluate the safety of fosfluconazole prophylaxis for preventing invasive fungal infection in VLBW infants with a central vascular access. Fosfluconazole was administered intravenously at a dose of 6 mg/kg everyday during which time a central venous catheter was placed. A total of 23 infants met the criteria for enrollment in our study. No cases of fungal infection were detected during the central venous catheter placement in the group. None of the infants had an elevatedβ-D-glucan, and all of them were still alive at discharge. Regarding the l

Style APA, Harvard, Vancouver, ISO itp.

36

Sutarsa, I. Nyoman. "Where do we go with HIV pre-exposure prophylaxis in Indonesia?" Public Health and Preventive Medicine Archive 5, no. 2 (2017): 77–78. http://dx.doi.org/10.53638/phpma.2017.v5.i2.p01.

Pełny tekst źródła

Streszczenie:

PrEP is an effective additional prevention strategy at trial settings. Decision to adopt PrEP as a public health intervention must be made based on the need and capacity of current systems. Instead of allocating substantial resources for PrEP, the limited resources could be wisely allocated to scale-up the existing prevention strategies including access to ART, as well as to ensure equality of access of people to full-range of HIV prevention and treatment measures.

Style APA, Harvard, Vancouver, ISO itp.

37

Paul, Lincy, Vijayakumar Narayana Pillai, Rema Ganapathy, et al. "Comparison of Improvement in Hemophilia Care in Children over a Decade and Outcomes - a Retrospective Study from Southern Part of India." Blood 144, Supplement 1 (2024): 5484. https://doi.org/10.1182/blood-2024-212030.

Pełny tekst źródła

Streszczenie:

Background: Hemophilia, an X-linked recessive bleeding disorder, presents significant challenges in management but can be mitigated with appropriate clotting factor replacement therapy. Resource limited settings across the world face unique challenges in implementing prophylaxis as the standard of care. The objective of this study is to assess the improvement in prophylaxis and comprehensive care of children with Hemophilia(CwH) attached to a newly established Hemophilia Treatment Center (HTC) in India during the last decade. Methodology: Study was retrospective from January 2015 to June 2024.

Style APA, Harvard, Vancouver, ISO itp.

38

McBride, Ali, Karen MacDonald, and Ivo Abraham. "Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate." Blood 136, Supplement 1 (2020): 22. http://dx.doi.org/10.1182/blood-2020-142749.

Pełny tekst źródła

Streszczenie:

Introduction: Approvals of biosimilar pegfilgrastim products in recent years have reduced the costs of single-dose prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN). While reference pegfilgrastim with on-body injector (PEG-OBI) offers convenience to patients over use of next day pre-filled syringe (PFS), PEG-OBI has a reported failure rate of 1.7-6.9% that predisposes patients to increased risk of CIN/FN episodes. Incremental FN-related hospitalizations (FN-HOSP) associated with PEG-OBI failure contribute to the cost differential between PEG-OBI and assured prophylaxis with bi

Style APA, Harvard, Vancouver, ISO itp.

39

Grossman, Katlyn H. "987. Improving Patient Access to HIV Post-Exposure Prophylaxis with Pharmacist Involvement." Open Forum Infectious Diseases 7, Supplement_1 (2020): S522. http://dx.doi.org/10.1093/ofid/ofaa439.1173.

Pełny tekst źródła

Streszczenie:

Abstract Background Appropriate use of post-exposure prophylaxis (PEP) after isolated sexual, injection drug use, or other exposures to HIV is an effective tool to reduce the risk of HIV acquisition. PEP completion rates are low, with literature reporting only 40% of sexual assaulted persons adhering to a full 28-day course. One important barrier to adherence can be access to medications in a timely manner. In the United States, a four week course of PEP costs nearly $4,000 without insurance and can remain unaffordable with high copays and deductibles for patients who are underinsured. Methods

Style APA, Harvard, Vancouver, ISO itp.

40

Haire, Bridget. "National leadership needed on HIV Pre-exposure Prophylaxis (PrEP) access in Australia." Australian and New Zealand Journal of Public Health 40, no. 6 (2016): 504–5. http://dx.doi.org/10.1111/1753-6405.12570.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Scully, Eileen P., Ethel D. Weld, and Joel N. Blankson. "Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention." Journal of Clinical Investigation 129, no. 12 (2019): 5071–73. http://dx.doi.org/10.1172/jci134389.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Scaife, Courtney L., Molly E. Gross, Mary C. Mone, et al. "Antibiotic prophylaxis in the placement of totally implanted central venous access ports." American Journal of Surgery 200, no. 6 (2010): 719–23. http://dx.doi.org/10.1016/j.amjsurg.2010.07.023.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Tung, Elyse L., Annalisa Thomas, Allyson Eichner, and Peter Shalit. "Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care." Sexual Health 15, no. 6 (2018): 556. http://dx.doi.org/10.1071/sh18084.

Pełny tekst źródła

Streszczenie:

Background National guidelines for the provision of HIV pre-exposure prophylaxis (PrEP) to reduce a person’s risk of acquiring HIV were made available in 2014. We created a pharmacist-managed HIV PrEP clinic in a community pharmacy setting at Kelley-Ross Pharmacy in Seattle, WA, USA. Methods: The clinic operates under a collaborative drug therapy agreement based on these guidelines. This allows pharmacists to initiate and manage tenofovir disoproxil fumarate/emtricitabine under the supervision of a physician medical director. Results: Between March 2015 and February 2018, 714 patients were eva

Style APA, Harvard, Vancouver, ISO itp.

44

Clarke-Steffen, Laura, Veenod Chulani, Michael Dobbs, and Janice Piatt. "Barriers Encountered By Youth Aged 13–24 While Accessing Pre-Exposure Prophylaxis to HIV: Phoenix Pre-Exposure Prophylaxis Access Project." AIDS Patient Care and STDs 37, no. 9 (2023): 432–35. http://dx.doi.org/10.1089/apc.2023.0131.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Ragni, Margaret V., Patrick F. Fogarty, Neil C. Josephson, Anne T. Neff, Leslie Raffini, and Craig M. Kessler. "Survey of Current Prophylaxis Practices and Bleeding Characteristics of Children with Severe Hemophilia A In U.S. Hemophilia Treatment Centers." Blood 116, no. 21 (2010): 3653. http://dx.doi.org/10.1182/blood.v116.21.3653.3653.

Pełny tekst źródła

Streszczenie:

Abstract Abstract 3653 Introduction: Every other day (qod) factor VIII prophylaxis prevents joint bleeds in children with severe hemophilia A. Although three times weekly or qod prophylaxis is recommended by the National Hemophilia Foundation (NHF), how widely these practices have been adopted is not known. Aim: We sought to define current prophylaxis practices at U.S. Hemophilic Treatment Centers (HTCs). Method: An email survey was distributed to U.S. HTCs, utilizing web-based membership rosters of the Centers for Disease Control (CDC) and the Hemophilia Thrombosis Research Society (HTRS). Re

Style APA, Harvard, Vancouver, ISO itp.

46

Fasola, Gianpiero, Chiara Savignano, Maria Gloria Revignas, Luigi Virgolini, and Michele Baccarani. "Infections in Patients with Acute Non-Lymphocytic Leukemia Nursed with Central or Peripheral Venous Access." Tumori Journal 79, no. 2 (1993): 112–15. http://dx.doi.org/10.1177/030089169307900206.

Pełny tekst źródła

Streszczenie:

Aims and Background Infections are a major problem in patients undergoing induction chemotherapy for acute leukemia. Granulocytopenia is the single most imporant risk factor, but the pattern of infecting organisms can change according to nursing facilities or bacterial and fungal prophylaxis. Methods We reviewed the patterns and types of infections in 30 patients with acute non-lymphocytic leukemia. Eighty-nine periods of neutropenia following chemotherapy were evaluated: in 60 courses patients had central and in 29 had peripheral venous access. Results Almost all patients (97 %) became febril

Style APA, Harvard, Vancouver, ISO itp.

47

Cultrera, Dorina, Raimondo De Cristofaro, Paola Giordano, et al. "Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly." Reports — Medical Cases, Images, and Videos 3, no. 1 (2020): 3. http://dx.doi.org/10.3390/reports3010003.

Pełny tekst źródła

Streszczenie:

This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy. These centers were given a questionnaire consisting of ten closed multiple-choice questions. The centers were asked: (a) the percentages of their hemophilia B (HB) patients undergoing replacement therapy, “On-demand”, or weekly prophylaxis, (b) the criteria guiding the monitoring of patients, the advantages according to the age of patients, and (c) the obstacles to prophylaxis. The percentage of pat

Style APA, Harvard, Vancouver, ISO itp.

48

Rujumba, Joseph, Ruth Namazzi, Deogratias Munube, et al. "Caregivers and Healthcare Workers Experiences and Preferences with Use of Penicillin Prophylaxis in Young Children with Sickle Cell Anemia in Uganda." Blood 144, Supplement 1 (2024): 3629. https://doi.org/10.1182/blood-2024-208912.

Pełny tekst źródła

Streszczenie:

Introduction: Bacterial infections are a major cause of sickle cell anemia related morbidity and mortality in young children with sickle cell anemia (SCA) in Sub-Saharan Africa. Penicillin prophylaxis is therefore recommended as a standard of care for all SCA children who are less than five years of age. Despite the proven benefit, compliance to penicillin prophylaxis remains poor among SCA children in sub-Saharan Africa. There is therefore, a need to investigate reasons for the poor compliance to penicillin prophylaxis in order to inform interventions to improve adherence. We explored the exp

Style APA, Harvard, Vancouver, ISO itp.

49

Tolani. "Clinical Audit of Low Dose Prophylaxis Programme for Nigerian Children with Haemophilia." West Africa Journal of Medicine 39, no. 1 (2022): 11–15. http://dx.doi.org/10.55891/wajm.v39i1.86.

Pełny tekst źródła

Streszczenie:

Introduction: The evidence of benefits for prophylaxis especially low dose prophylaxis is incontestable yet most children in developing countries as Nigeria do not have access to this treatment protocol. Aim: The aim was to audit the low dose prophylaxis treatment in Nigerian children with haemophilia. Methodology: A multicentre clinical audit of five haemophilia treatment centres; University of Nigeria Teaching Hospital Enugu, Lagos University Teaching Hospital, National Hospital Abuja, University of Port Harcourt Teaching Hospital Port Harcourt, and Federal Teaching Hospital Gomb

Style APA, Harvard, Vancouver, ISO itp.

50

Malloy, Giovanni S. P., Margaret L. Brandeau, and Jeremy D. Goldhaber-Fiebert. "Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar." Tropical Medicine and Infectious Disease 6, no. 2 (2021): 101. http://dx.doi.org/10.3390/tropicalmed6020101.

Pełny tekst źródła

Streszczenie:

Plague (Yersinia pestis) remains endemic in certain parts of the world. We assessed the cost-effectiveness of plague control interventions recommended by the World Health Organization with particular consideration to intervention coverage and timing. We developed a dynamic model of the spread of plague between interacting populations of humans, rats, and fleas and performed a cost-effectiveness analysis calibrated to a 2017 Madagascar outbreak. We assessed three interventions alone and in combination: expanded access to antibiotic treatment with doxycycline, mass distribution of doxycycline pr

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!